Get started
Author

Christopher Halliday

Observed names: CHRISTOPHER HALLIDAY, Halliday, Christopher
OpenAlex ID: A5112335251
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection
2021 · Richard J. Mills, Sean J. Humphrey, et al. · Cell · 227
PDF
Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism
2019 · Laura M. Tsujikawa, Li Fu, et al. · Clinical Epigenetics · 128
PDF
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease
2016 · Dean Gilham, Sylwia Wasiak, et al. · Atherosclerosis · 117
Apabetalone downregulates factors and pathways associated with vascular calcification
2018 · Dean Gilham, Laura M. Tsujikawa, et al. · Atherosclerosis · 65
PDF
Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)
2017 · Sylwia Wasiak, Dean Gilham, et al. · Journal of Cardiovascular Translational Research · 51
PDF
Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease
2018 · Ewelina Kulikowski, Christopher Halliday, et al. · Kidney & Blood Pressure Research · 46
Benefit of Apabetalone on Plasma Proteins in Renal Disease
2017 · Sylwia Wasiak, Laura M. Tsujikawa, et al. · Kidney International Reports · 42
PDF
Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease
2019 · Mathias Haarhaus, Kausik K. Ray, et al. · Atherosclerosis · 38
PDF
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial
2021 · Gregory G. Schwartz, Stephen J. Nicholls, et al. · Cardiovascular Diabetology · 28
PDF
Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes
2016 · Sylwia Wasiak, Dean Gilham, et al. · Data in Brief · 17
PDF
Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro , in Mice and in Patients with Cardiovascular Disease
2020 · Sylwia Wasiak, Dean Gilham, et al. · Cardiovascular Therapeutics · 15
PDF
Corrigendum to “RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease” [Atherosclerosis 247 (2016) 48–57]
2016 · Dean Gilham, Sylwia Wasiak, et al. · Atherosclerosis · 5
Sp071apabetalone (rvx-208), a Selective Bromodomain and Extra-terminal (bet) Protein Inhibitor, Decreases Abundance and Activity of Complement Proteins in Vitro, in Mice and in Clinical Studies
2016 · Norman Cw Wong, Kamyar Kalantar-Zadeh, et al. · Nephrology Dialysis Transplantation · 3
PDF
Apabetalone, an Epigenetic Bet Inhibitor in a Phase 3 Trial, Inhibits Vascular Inflammation and Cellular Adhesion Leading to Beneficial Outcomes in Cvd Patients
2019 · Laura Tsujikawa, Li Fu, et al. · Journal of the American College of Cardiology · 2
PDF
Sp425effects of Apabetalone (rvx-208) on Serum Albumin in Subjects With Cvd, Diabetes and Chronic Kidney Disease; a Post-hoc Analysis of the Assure and Sustain Clinical Trials
2017 · Ewelina Kulikowski, Christopher Halliday, et al. · Nephrology Dialysis Transplantation · 2
PDF
Apabetalone (rvx-208) Lowers Cardiovascular Disease (cvd) in Diabetes Mellitus by a Mechanism Involving Microbiome Mediated Activity on the Complement Pathway
2017 · Norman C. Wong, Ewelina Kulikowski, et al. · Journal of the American College of Cardiology · 2
PDF
Fp330apabetalone, a Selective Bromodomain and Extra-terminal (bet) Protein Inhibitor, Reduces Serum Fgf23 in Cardiovascular Disease and Chronic Kidney Disease Patients
2019 · Kamyar Kalantar-Zadeh, Carmine Zoccali, et al. · Nephrology Dialysis Transplantation · 1
Abstract 671: Hepatic Expression of C-Reactive Protein is Epigenetically Regulated by BET Proteins and Inhibited by Apabetalone (RVX-208) in vitro and in CVD Patients
2019 · Sylwia Wasiak, Dean Gilham, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 1
Apabetalone (RVX-208) Lowers Risk of Major Adverse Cardiovascular Events (MACE) in T2D Patients with CVD By Attenuating Monocyte Adhesion to Endothelial Cells
2018 · Laura Tsujikawa, Ewelina Kulikowski, et al. · Atherosclerosis Supplements · 1
BET inhibitor apabetalone (RVX-208) downregulates the complement cascade in primary human hepatocytes, in mice and in cardiovascular disease human patients
2017 · Sylwia Wasiak, Dean Gilham, et al. · Molecular Immunology · 1
Abstract 163: Apabetalone (RVX-208) Has Anti-atherosclerotic, Anti-Thrombotic and Anti-Inflammatory Effects in Patients With Cardiovascular Disease (CVD)
2016 · Ewelina Kulikowski, Sylwia Wasiak, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 1
Abstract 338: Effects of RVX-208 a Selective Bromodomain Extra-Terminal Protein Inhibitor Beyond Raising ApoA-I/HDL.
2015 · Norman C Wong, Ewelina Kulikowski, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 1
Permissive Blood Pressure Targets in Pediatric Critical Care
2026 · David P. Inwald, Emma Laing, et al. · JAMA
PDF
Mo072apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells Which May Contribute to Reduced Cardiac Events Observed in Ckd Patients
2021 · Dean Gilham, Li Fu, et al. · Nephrology Dialysis Transplantation
Apabetalone, an Inhibitor of BET Proteins, Downregulates Alkaline Phosphatase and Improves Cardiovascular Risk
2020 · Dean Gilham, Laura Tsujikawa, et al. · Journal of the American Society of Nephrology
Works count: 55
Citation count: 794
H-index: 11
I10-index: 11
Year
Topic
Type